title: Profile of differentially expressed intratumoral cytokines to predict the immune-polarizing side effects of tamoxifen in breast cancer treatment.
abstract: Factors within the tissue of breast cancer (BC) may shift the polarization of CD4+ T cells towards Th2 direction. This tendency can promote tumor development and be enhanced by the use of tamoxifen during the treatment. Thus, the patients with low levels of tumor-induced Th2 polarization prior to tamoxifen treatment may better endure the immune-polarizing side effects (IPSE) of tamoxifen and have better prognoses. Estimation of Th2 polarization status should help predict the IPSE among tamoxifen-treated patients and guide the use of tamoxifen among all BC patients before the tamoxifen therapy. Here, we report profiling of differentially expressed (DE) intratumoral cytokines as a signature to evaluate the IPSE of tamoxifen. The DE genes of intratumoral CD4+ T cells (CD4 DEGs) were identified by gene expression profiles of purified CD4+ T cells from BC patients and validated by profiling of cultured intratumoral CD4+ T cells. Functional enrichment analyses showed a directed Th2 polarization of intratumoral CD4+ T cells. To find the factors inducing the Th2 polarization of CD4+ T cells, we identified 995 common DE genes of bulk BC tissues (BC DEGs) by integrating five independent datasets. Five DE cytokines observed in bulk BC tissues with dysregulated receptors in the intratumoral CD4+ T cells were selected as the predictor of the IPSE of tamoxifen. The patients predicted to suffer low IPSE (low Th2 polarization) had a significantly lower distant relapse risk than the patients predicted to suffer high IPSE in independent datasets (n = 608; HR = 4.326, P = 0.000897; HR = 2.014, P = 0.0173; HR = 2.72, P = 0.04077). Patients predicted to suffer low IPSE would benefit from tamoxifen treatment (HR = 2.908, P = 0.03905). The DE intratumoral cytokines identified in this study may help predict the IPSE of tamoxifen and justify the use of tamoxifen in BC treatment.
authors.affiliation: Genomics Research Center (One of The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University China.
authors.forename: Bailiang
authors.initials: B
authors.lastname: Li
authors.affiliation: College of Bioinformatics Science and Technology, Harbin Medical University Harbin, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Li
authors.affiliation: Genomics Research Center (One of The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University China.
authors.forename: Xiao-Yu
authors.initials: XY
authors.lastname: Wang
authors.affiliation: Genomics Research Center (One of The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University China.
authors.forename: Zi-Qiao
authors.initials: ZQ
authors.lastname: Yan
authors.affiliation: Genomics Research Center (One of The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University China.
authors.forename: Huidi
authors.initials: H
authors.lastname: Liu
authors.affiliation: Genomics Research Center (One of The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University China.
authors.forename: Gui-Rong
authors.initials: GR
authors.lastname: Liu
authors.affiliation: Genomics Research Center (One of The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University China ; Department of Microbiology, Immunology and Infectious Diseases, University of Calgary Calgary, Canada.
authors.forename: Shu-Lin
authors.initials: SL
authors.lastname: Liu
keywords: Breast cancer; cytokine; gene expression profiles; immune-polarizing side effects; tamoxifen; the CD4+ T cell